Abstract:Prion diseases are caused by the conversion of normal cellular prion proteins (PrP) into lethal prion aggregates. These prion aggregates are composed of proteinase K (PK) resistant fibrils and comparatively PK-sensitive oligomers. Currently there are no anti-prion pharmaceuticals available to treat or prevent prion disease. Methods of discovering anti-prion molecules rely primarily on relatively complex cell-based, tissue slice or animal-model assays that measure the effects of small molecules on the formation of PK-resistant prion fibrils. These assays are difficult to perform and do not detect the compounds that directly inhibit oligomer formation or alter prion conversion kinetics. We have developed a simple cell-free method to characterize the impact of anti-prion fibril compounds on both the oligomer and fibril formation. In particular, this assay uses shaking-induced conversion (ShIC) of recombinant PrP in a 96-well format and resolution enhanced native acidic gel electrophoresis (RENAGE) to generate, assess and detect PrP fibrils in a high throughput fashion. The end-point PrP fibrils from this assay can be further characterized by PK analysis and negative stain transmission electron microscopy (TEM). This cell-free, gel-based assay generates metrics to assess anti-prion fibril efficacy and kinetics. To demonstrate its utility, we characterized the action of seven well-known anti-prion molecules: Congo red, curcumin, GN8, quinacrine, chloropromazine, tetracycline, and TUDCA (taurourspdeoxycholic acid), as well as four suspected anti-prion compounds: trans-resveratrol, rosmarinic acid, myricetin and ferulic acid. These findings suggest that this in vitro assay could be useful in identifying and comprehensively assessing novel anti-prion fibril compounds. Abbreviations: PrP, prion protein; PK, proteinase K; ShIC, shaking-induced conversion; RENAGE, resolution enhanced native acidic gel electrophoresis; TEM, transmission electron microscopy; TUDCA, taurourspdeoxycholic acid; BSE, bovine spongiform encephalopathy; CWD, chronic wasting disease; CJD, Creutzfeldt Jakob disease; GSS, Gerstmann-Sträussler-Scheinker syndrome; FFI, fatal familial insomnia; PrPc, cellular prion protein; recPrPC, recombinant monomeric prion protein; PrPSc, infectious particle of misfolded prion protein; RT-QuIC, real-time quaking-induced conversion; PMCA, Protein Misfolding Cyclic Amplification; LPS, lipopolysaccharide; EGCG, epigallocatechin gallate; GN8, 2-pyrrolidin-1-yl-N-[4-[4-(2-pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide; DMSO, dimethyl sulfoxide; ScN2A, scrapie infected neuroblastoma cells; IC50, inhibitory concentration for 50% reduction; recMoPrP 23-231, recombinant full-length mouse prion protein residues 23-231; EDTA; PICUP, photo-induced cross-linking of unmodified protein; BSA, bovine serum albumin;; PMSF, phenylmethanesulfonyl fluoride.

Development of a methodology for large-scale production of prions for biological and structural studies

Protein Misfolding Cyclic Amplification Cross-Species Products of Mouse-Adapted Scrapie Strain 139A and Hamster-Adapted Scrapie Strain 263K with Brain and Muscle Tissues of Opposite Animals Generate Infectious Prions

PrP(Sc) of Scrapie 263K Propagates Efficiently in Spleen and Muscle Tissues with Protein Misfolding Cyclic Amplification.

Expression of PrP(C) As HIS-fusion Form in a Baculovirus System and Conversion of Expressed PrP-sen to PrP-res in a Cell-Free System.

Understanding Intra-Species and Inter-Species Prion Conversion and Zoonotic Potential Using Protein Misfolding Cyclic Amplification

A Protein Misfolding Shaking Amplification-based method for the spontaneous generation of hundreds of bona fide prions

De Novo Generation of Infectious Prions with Bacterially Expressed Recombinant Prion Protein

Screening of Anti-Prion Compounds Using the Protein Misfolding Cyclic Amplification Technology

Adaptation of the protein misfolding cyclic amplification (PMCA) technique for the screening of anti-prion compounds

Comparison of 2 synthetically generated recombinant prions.

Generating A Prion With Bacterially Expressed Recombinant Prion Protein

Hyperefficient PrP Sc amplification of mouse-adapted BSE and scrapie strain by protein misfolding cyclic amplification technique

Direct Observation Of Murine Prion Protein Replication In Vitro

A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds

The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases

PMCA to demonstrate prions inactivation method efficacy on reusable medical devices: a relevant alternative to animal bioassays

Role of prion protein glycosylation in replication of human prions by protein misfolding cyclic amplification

Amplification Techniques for the Detection of Misfolded Prion Proteins in Experimental and Clinical Samples

Exploration of the main sites for the transformation of normal prion protein (PrP<sup>C</sup>) into pathogenic prion protein (PrP<sup>sc</sup>)

Detection of Pathognomonic Biomarker PrPSc and the Contribution of Cell Free-Amplification Techniques to the Diagnosis of Prion Diseases

Exploration Of The Main Sites For The Transformation Of Normal Prion Protein (Prpc) Into Pathogenic Prion Protein (Prpsc)